TD Private Client Wealth LLC Raises Holdings in Hologic, Inc. (NASDAQ:HOLX)

TD Private Client Wealth LLC boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2,374.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,825 shares of the medical equipment provider’s stock after acquiring an additional 4,630 shares during the quarter. TD Private Client Wealth LLC’s holdings in Hologic were worth $393,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FMR LLC raised its position in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Black Creek Investment Management Inc. increased its stake in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its holdings in Hologic by 1,023.3% in the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the period. Marshall Wace LLP purchased a new position in Hologic during the second quarter worth approximately $39,427,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Hologic by 21.6% in the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after purchasing an additional 450,190 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Down 1.9 %

Shares of NASDAQ:HOLX opened at $73.65 on Friday. Hologic, Inc. has a 52-week low of $70.24 and a 52-week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The business has a fifty day moving average of $79.32 and a two-hundred day moving average of $78.59. The stock has a market cap of $16.71 billion, a P/E ratio of 22.12, a PEG ratio of 2.38 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.89 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.75% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Mizuho dropped their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, December 10th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.50.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.